Abstract
Aim:
To gain insight into the histopathological responses and molecular targets in the inhibition of growth of human gastric cancer treated with celecoxib (a cyclooxygenase [COX]-2 inhibitor) combined with octreotide.
Methods:
Seventy five patients with gastric cancer undergoing curative gastrectomy or extended resection were randomly divided into 3 groups. The apoptosis of tumor cells was measured by terminal deoxynucleotide transferase-mediated dUTP nick end-labeling (TUNEL) assay. Gastric cancer microvessel density (MVD) and the expression of COX-2 were evaluated by immunohistochemical staining. The expression of somatostatin receptor (SSTR)-2 was detected with the biomolecular interaction analysis system. The transcription of non-steroidal anti-inflammatory drug-activated gene (NAG)-1 was measured by RT-PCR.
Results:
Compared with the control and celecoxib groups, more necrosis in the combination group was observed. The apoptotic rate in the combination group (7.06%±0.67%) was significantly higher than that in the control group (6.23%±1.29%, P<0.05). The MVD decreased considerably in the combination group. The upregulation of NAG-1 was displayed both in the celecoxib and combination groups. The positive rate of SSTR-2 in gastric cancers treated with celecoxib (48%) was significantly higher than that of control group (12%) after surgery (P<0.05).
Conclusion:
Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarci-noma through the induction of apoptosis and the reduction of MVD. NAG-1 and SSTR-2 might be the molecular targets for celecoxib or octreotide.
Similar content being viewed by others
Article PDF
References
Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM . Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27–39.
Wohrer SS, Raderer M, Hejna M . Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15: 1585–95.
Liu CL, Tang CW, Wang CH, Zhou XC . The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adeno-carcinoma. J West China Univ Med Sci 2003; 3: 372–5. Chinese.
Baek SJ, Wilson LC, Lee CH, Eling TE . Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclo-oxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301: 1126–31.
Uefuji K, Ichikura T, Mochizuki H . Expression of cyclo-oxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001; 76: 26–30.
Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91: 1876–81.
Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M . Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999; 80: 448–54.
Pollak MN, Schally AV . Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998; 217: 143–52.
Tang C, Wang C, Tang L . Effects of combined octreotide and aspirin on the growth of gastric cancer. Chin Med J (Engl) 2003; 116: 373–7.
Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, et al. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer 1994; 57: 574–80.
Reisine T, Bell GI . Molecular biology of somatostatin receptors. Endocr Rev 1995; 16: 427–42.
Kwon KS, Chae HJ . Sodium salicylate inhibits expression of COX-2 through suppression of ERK and subsequent NF-kappaB activation in rat ventricular cardiomyocytes. Arch Pharm Res 2003; 26: 545–53.
Tang CW, Liu CL, Zhou XC, Wang CH . Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer 2004; 112: 470–4.
Gavrieli Y, Sherman Y, Beb-Sasson SA . Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493–501.
Hasan J, Byers R, Jayson GC . Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86: 1566–77.
Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res 2005; 11: 6472–8.
Casper D, Bukhtiyarova M, Springman EB . A Biacore biosensor method for detailed kinetic binding analysis of small molecule inhibitors of p38alpha mitogen-activated protein kinase. Anal Biochem 2004; 325: 126–36.
Sarbia M, Becker KF, Hofler H . Pathology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 465–75.
Jazowiecka-Rakus J, Jarosz M, Kozlowska D, Sochanik A, Szala S . Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors. Acta Biochim Pol 2007; 54: 125–33.
Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma — 2nd English Edition. Gastric Cancer 1998; 1: 10–24.
Diasio RB, Fourie J . Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs 2006; 66: 1441–63.
Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE . Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005; 67: 356–64.
Hu C, Yi C, Hao Z, Cao S, Li H, Shao X, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004; 3: 726–30.
Kouroumalis EA . Octreotide for cancer of the liver and biliary tree. Chemotherapy 2001; 47 Suppl 2: 150–61.
Wang CH, Tang CW, Liu CL, Tang LP . Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 2003; 9: 1904–8.
Liu C, Tang C, Zhou X, Wang C . Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Basic Med Sci Clin 2004; 24: 277–81. Chinese.
Gajraj NM . Cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96: 1720–38.
Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558–66.
Macdonald JS . Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004; 54 Suppl 1: S4–11.
Lindsey H . Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol 2004; 5: 519.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a grant from National Natural Science Foundation of China (No 30170418) and the Key Program from the Department of Science and Technology of Sichuan Province, China (No 02SG011-066).
Rights and permissions
About this article
Cite this article
Huang, Mt., Chen, Zx., Wei, B. et al. Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin 28, 1842–1850 (2007). https://doi.org/10.1111/j.1745-7254.2007.00652.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00652.x
Keywords
This article is cited by
-
Preoperative diagnosis of metastatic lymph nodes by CT-histopathologic matching analysis in gastric adenocarcinoma using dual-layer spectral detector CT
European Radiology (2023)
-
Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells
Digestive Diseases and Sciences (2009)